TGR-1202: Ph IIa started

TG Therapeutics said the University of Nebraska Medical Center began an open-label, U.S. Phase IIa trial to evaluate once-daily oral TGR-1202 plus once-daily oral Imbruvica ibrutinib in 28-day cycles ...